In the phase 2 trial conducted by Luminari et al.,20 15 out of 75 patients (21%) treated with R‐COMP (median age 72 years) presented cardiac AEs (grade 3–4 in 3 patients, corresponding to cardiac ischemia, atrial fibrillation, and congestive heart failure), whereas in the Austrian phase 3 trial,23 a total of 9 cardiac SAEs were observed, again without differences between R‐COMP (5 cardiac SAEs) and R‐CHOP (4 cardiac SAEs). The gene discussed is COMP; the disease is atrial fibrillation.